Build vs Buy Spectroscopy Software: Cost and Timeline Analysis

You have a working spectrometer, a trained classification model, and a team of scientists who can write code. The natural next thought: "We'll build the clinical workflow software ourselves."

This is a rational instinct. Your team understands the science better than any vendor. You want control over the roadmap. You have developers on staff. Building in-house feels like it will be faster, cheaper, and more aligned with your specific needs.

Sometimes it is. Most of the time, it is not — and the reason is not the software you can see. It is everything underneath it.

This article maps the full scope of what "build clinical workflow software for spectroscopy diagnostics" actually entails. Not the UI. Not the ML pipeline. The entire iceberg — instrument integration, regulatory documentation, EHR connectivity, cybersecurity, audit trails, and ongoing maintenance. The goal is to give you the cost and timeline data you need to make an informed decision, not to sell you on a particular answer.

The iceberg below the surface

When someone says "we need clinical workflow software," what they picture is a UI: patient identification, test execution, result display. That is the 15% above the waterline. Below it is a stack of integration, compliance, and infrastructure work that typically accounts for 85% of the total effort.

Here is what lives below the waterline.

Instrument integration

Your spectrometer was not designed to be controlled by clinical software. It was designed to be operated by a spectroscopist using vendor-provided desktop software. Automating it — acquiring spectra programmatically, monitoring instrument health, handling calibration state — requires interfacing with vendor APIs that range from poorly documented to actively hostile.

Bruker OPUS provides automation through DDE (Dynamic Data Exchange), a Windows interprocess communication protocol introduced in 1987. DDE is synchronous, fragile, and has no modern tooling support. Bruker also exposes COM automation, but the documentation assumes deep familiarity with the OPUS macro language and the experiment file format (.xpm) is proprietary binary. We have written a detailed Bruker OPUS integration guide — it took us months to figure out what that article covers in 20 minutes of reading.

Thermo Fisher OMNIC uses COM/ActiveX for automation. The transition from OMNIC to OMNIC Paradigm introduced breaking changes in the automation API, meaning code written for one version may not work with the next. If your hospital upgrades their Thermo software — which Thermo may push as part of a service contract — your integration breaks.

Horiba LabSpec uses TCP/IP sockets for remote control. This is architecturally cleaner than DDE, but the protocol has its own quirks around connection management, asynchronous acquisition callbacks, and error handling for instrument states that the documentation does not fully enumerate.

Renishaw WiRE has the most limited automation capabilities of the major vendors. Meaningful integration often requires working directly with Renishaw's application engineering team, which introduces scheduling dependencies and NDA constraints.

Each instrument integration is 2-4 weeks of focused R&D at minimum — if you have someone who has done it before. If you are starting from scratch, budget 3-6 months per vendor. That includes testing across firmware versions, handling every edge case (instrument not responding, acquisition timeout, calibration failure, unexpected spectral format changes), and building the abstraction layer that lets your software treat all instruments uniformly. For a deeper look at the vendor landscape, see our instrument vendor analysis.

HL7v2 message generation

A classification result that lives only in your software is clinically useless. It needs to reach the patient's chart in Epic, Cerner, MEDITECH, or whatever EHR the hospital uses. The transport mechanism is an HL7v2 ORU^R01 message — the observation result format that every laboratory information system in the United States has understood since the early 1990s.

Generating an HL7 message is not just string formatting. It is field mapping — assigning the right values to the right positions in the right segments, conforming to the expectations of the specific receiving system at the specific hospital. Those expectations vary by EHR vendor, by LIS vendor, by hospital, and sometimes by department within a hospital.

Here is what a properly formatted ORU^R01 message looks like for an FTIR-based classification result:

MSH|^~\&|SPECTRADX|LAB01|EPIC|HOSP01|20260606120000||ORU^R01^ORU_R01|MSG00001|P|2.5.1|||AL|NE
PID|1||MRN123456^^^HOSP01^MR||DOE^JANE^||19850315|F
OBR|1|ORD789012|SPE456789|FTIR_STREP^FTIR Strep A Detection^L|||20260606115500|||||||20260606115800||1234567890^SMITH^JOHN^D^MD||||||20260606120000|||F
OBX|1|CWE|FTIR_RESULT^FTIR Classification^L||STREP_POS^Streptococcus pyogenes Detected^L|||A|||F|||20260606115945
OBX|2|NM|FTIR_CONF^Classification Confidence^L||97.3|%|95-100|N|||F|||20260606115945
OBX|3|NM|FTIR_HQI^Hit Quality Index^L||947||900-1000|N|||F|||20260606115945
NTE|1||Specimen: Throat swab. Method: ATR-FTIR with ML classification.

If you have not worked with HL7 before, this probably looks like line noise. Here is what each segment does:

• MSH (Message Header): Identifies the sending system (SPECTRADX), receiving system (EPIC), message type (ORU^R01), and HL7 version (2.5.1). The message control ID (MSG00001) must be globally unique — the receiving system uses it for deduplication.
• PID (Patient Identification): Links the result to a patient by MRN. Get this wrong and the result goes to the wrong chart.
• OBR (Observation Request): Describes the test that was ordered — the order number, specimen accession number, test code, ordering provider, and result status (F = Final).
• OBX (Observation Result): The actual results. You typically need multiple OBX segments — one for the classification (CWE = coded with exceptions), one for the confidence score (NM = numeric), and one for spectral quality metrics.
• NTE (Notes and Comments): Free-text notes about specimen type and methodology.

Every pipe, every caret, every field position matters. An OBX segment with the wrong data type indicator (CE vs. CWE vs. ST) will be rejected by the interface engine. A PID segment with the MRN in the wrong sub-field will fail patient matching. A message without proper acknowledgment handling will silently disappear.

The cost baseline for HL7 integration: $48K-$58K for a simple, single-site connection with cooperative IT staff. That scales to $50K-$750K+ for complex integrations involving multiple receiving systems, custom message transformations, and bidirectional order-result workflows. Timeline: 3-6 months per site for the first integration, 1-3 months for subsequent sites once you have the patterns established. Our HL7v2 integration guide covers the full technical implementation.

FHIR R4 resources

HL7v2 gets you connected today. FHIR R4 is what you need for tomorrow. CMS mandates FHIR API implementation for certified health IT, with enforcement extending through January 2027. The relevant resources — DiagnosticReport, Observation, Specimen, Device — require careful mapping, and spectroscopy classification results do not fit neatly into existing FHIR profiles designed for conventional lab results. You need custom extensions for spectral quality metrics, classification confidence, and instrument metadata. See our FHIR R4 spectroscopy guide for the resource mapping details.

Building both HL7v2 and FHIR from scratch doubles your interoperability development cost.

Patient workflow UI

The UI is the part everyone remembers to budget for. What they underestimate is how constrained it must be.

This is not a spectroscopy application for scientists. It is a clinical tool for medical technologists — many of whom have less than a year of experience, are running 50-200 tests per shift, and have no spectroscopy training. The interface must support the entire workflow — MRN entry (manual and barcode), test ordering, sample placement confirmation, acquisition progress, result display, result review, and result release — in under 90 seconds per test.

The 90-second rule is not aspirational. It is a deployment requirement. Every second you add to the per-test workflow multiplies across the daily test volume. At 100 tests per day, adding 30 seconds per test adds 50 minutes to the technologist's shift. They will stop using your system. See our clinical workflow architecture article for how this drives every design decision.

Billing automation

A test that runs but does not generate a billable event is a test that loses money. Each spectroscopy diagnostic test needs proper CPT coding, payer-specific modifier logic, and routing to the hospital's billing system. CPT code selection for novel spectroscopy tests is not straightforward — you may need to use existing codes (87880 for Strep A, for example) or apply for new PLA (Proprietary Laboratory Analyses) codes, which takes 6-9 months through the AMA process.

Multi-site data synchronization

If you deploy at more than one site — and you will need to for clinical validation studies and commercial rollout — you need centralized spectral databases, method version management, analytics dashboards, and a mechanism to deploy updated classification models to all sites simultaneously without disrupting operations. This is distributed systems engineering, and it is where in-house builds frequently stall.

Audit trail (21 CFR Part 11)

If your software produces electronic records used in clinical decision-making, those records must comply with 21 CFR Part 11. This means every action — result creation, modification, deletion, user login, system configuration change — must be logged with a timestamp, the identity of the person who performed it, and the reason for the action. The audit trail must be tamper-evident, meaning no user (including administrators) can modify or delete audit entries.

The FDA is not treating this as a formality. In FY2025, the agency issued 303 drug warning letters — a 59% increase over FY2024. Data integrity violations appear in approximately 15% of all warning letters. The enforcement trend is accelerating.

A concrete example: Person & Covey received an FDA warning letter in September 2025 because "there was never a formal procedure for Data Integrity" and all laboratory personnel shared a single common password for accessing electronic systems. No unique user identification. No audit trail attribution. No access controls. This is exactly the kind of finding that destroys a company's ability to market a regulated product.

Building a compliant audit trail is not adding a logging library. It is designing an append-only, cryptographically verifiable record system with role-based access controls, electronic signature capabilities, and the ability to produce a complete history of any record on demand for an FDA auditor. Most development teams underestimate this by 3-6 months.

Cybersecurity

HIPAA compliance has tightened substantially. Under the proposed 2025 Security Rule update — the first major revision since the 2013 Omnibus Rule — encryption at rest and in transit is mandatory, not "addressable." Multi-factor authentication is required for all access to ePHI. Annual penetration testing is required, not recommended. Vulnerability scanning must occur at least every six months.

For FDA submissions, you now need a Software Bill of Materials (SBOM) documenting every third-party component in your software. This is not optional — the FDA's 2023 cybersecurity guidance made SBOMs a required element of premarket submissions. Every open-source library, every SDK, every runtime dependency must be cataloged with version numbers and known vulnerability status.

If your software qualifies as SaMD

If your classification algorithm influences clinical decision-making — and if it is spectroscopy-based diagnostics, it almost certainly does — your software is likely Software as a Medical Device (SaMD) under FDA's framework. This triggers IEC 62304 lifecycle requirements: formal software development planning, requirements traceability, design reviews, unit and integration testing documentation, and a structured release process.

The timeline impact is severe. The average time-to-market for SaMD is approximately 3 years, and 66% of SaMD projects exceed that 3-year mark. This is not development time — this is the total elapsed time from project initiation to cleared product, including all the regulatory documentation, clinical validation, and submission cycles.

If you are building in-house, every line of code your team writes must be developed under IEC 62304 process controls. That means requirements documents before coding, traceability matrices linking requirements to tests, design review records, and change control procedures for every modification. Your scientists are now writing regulatory documentation instead of doing science. See our SaMD classification guide for how software architecture decisions determine your regulatory path.

The real cost comparison

With the full scope visible, here is what the three options actually cost.

The in-house build cost assumes 2-3 full-time engineers for 6-12 months at fully loaded costs of $150-200K per engineer per year. It does not cover the opportunity cost of those engineers not working on your core product.

The custom dev shop cost assumes a competent medical device software consultancy. The $250K floor is a minimal viable product — one instrument vendor, one EHR integration, basic compliance. The $500K ceiling is multi-vendor, multi-site, fully compliant — and even that may be optimistic if scope grows during development, which it always does.

Break-even analysis

The SpectraDx platform costs $3-5K per month ($36-60K per year) plus a one-time implementation fee of $15-25K. Year one total: $51-85K.

A custom build costs $250-600K upfront plus $50-200K per year in maintenance. Year one total: $300-800K.

The platform approach is cheaper in year one by $215-715K. It remains cheaper in year two, year three, and effectively every year after that, because the maintenance cost of custom software grows over time (technical debt, staff turnover, new compliance requirements, instrument vendor changes) while the platform cost remains predictable.

The crossover point — where in-house becomes cheaper than a platform — only arrives if you have a sufficiently large engineering team to absorb the maintenance cost as a fraction of existing headcount, and if your workflow requirements are so specialized that no platform can accommodate them. For most spectroscopy diagnostic companies, that crossover point does not exist within a realistic planning horizon.

The timeline comparison

Time-to-deployment is often more important than cost. Every month of delay is a month of forgone revenue, a month your competitors use to establish market presence, and a month closer to your runway expiring.

In-house build: 12+ months

Total: 12 months if nothing goes wrong. Things always go wrong. Instrument vendors release firmware updates that break your integration. The hospital's interface engine has undocumented quirks. Your HL7 messages pass unit tests but fail when the LIS applies its own validation rules. A realistic in-house timeline is 12-18 months, with significant risk of extending to 24 months.

If your software is SaMD and requires IEC 62304 compliance, add 6-12 months for regulatory documentation and design control processes. You are now at 18-30 months.

SpectraDx platform: 4-8 weeks

Total: 8 weeks. This is possible because the instrument adapters, HL7 engine, audit trail, and compliance infrastructure already exist. Site-specific work is configuration, not development.

The timeline difference is not just about speed. It is about what your team does during those months. In the in-house scenario, your scientists and engineers spend 12-18 months writing instrument drivers, HL7 parsers, and audit trail systems. In the platform scenario, they spend those same months on FDA submission preparation, clinical validation studies, and fundraising — the activities that actually move your company toward market.

When building in-house makes sense

Intellectual honesty requires acknowledging that in-house development is the right choice for some organizations. Here are the conditions under which it makes sense.

You have a 20+ person engineering team and spectroscopy software is your core product. If you are Bruker, Thermo Fisher, or Horiba — or aspire to be — building your own clinical workflow platform is a strategic asset, not a cost center.

Your workflow is genuinely unique and no platform can accommodate it. Not "we want the button in a different place" unique — that is configuration. Genuinely unique, meaning your clinical workflow has requirements that fundamentally differ from the acquire-classify-report paradigm. This is rarer than people think.

You have an existing QMS and IEC 62304 infrastructure. If your organization already operates under ISO 13485 with established design controls, change management procedures, and a regulatory affairs team that knows how to document software lifecycle processes, the incremental cost of building clinical workflow software under that infrastructure is lower than starting from zero.

Regulatory documentation is already part of your development process. If your engineers are already writing requirements specifications, maintaining traceability matrices, and conducting design reviews as part of their daily workflow, the compliance overhead of building clinical software is absorbed into existing processes rather than added as a new burden.

You intend to sell the software itself as a product or competitive differentiator. If the clinical workflow layer is part of your value proposition to customers — not just a means to deliver diagnostic results — then owning that layer has strategic value beyond its development cost.

If none of these conditions apply — if you are a 5-15 person diagnostic startup trying to get your first test to market — building clinical workflow software in-house is almost certainly the wrong allocation of resources. Your scientists should be optimizing classification models and running clinical validation studies, not writing HL7 parsers.

The opportunity cost

The cost comparison above captures direct expenses: development dollars, engineering salaries, platform fees. It does not capture the most important cost — opportunity cost.

Every month your scientists spend on software is a month not spent on your core mission. For a spectroscopy diagnostic startup, the core mission is proving that your test works, getting regulatory clearance, and reaching the market. Clinical validation studies, FDA submissions, and reimbursement strategy are the activities that determine whether your company succeeds. Clinical workflow software is necessary infrastructure, but it is not the thing that makes your science valuable.

The SaMD timeline penalty is severe. If your classification software qualifies as SaMD — and for spectroscopy diagnostics, it almost certainly does — the average time-to-market is approximately 3 years, with 66% of projects exceeding that timeline. Every month of software development that could be avoided pushes your revenue further into the future. If you are venture-funded, that is runway you cannot afford to burn on solved problems.

Your competitors are not waiting. The clinical spectroscopy market is moving. Vita Imaging is running FDA clinical trials for Raman-based melanoma detection. Spectral AI submitted a De Novo for multispectral burn wound assessment. Multiple FTIR-based pathogen identification systems are in clinical validation. While you are debugging HL7 message formatting, your competitors are enrolling patients in pivotal studies.

The cost is cumulative. A 12-month delay means 12 months of forgone revenue. At modest test volumes — 50 tests per day at $25 reimbursement — that is $456K per year per site. Multi-site deployment compounds the number rapidly.

The full picture of what it takes to cross from prototype to deployed clinical product is covered in our research-to-clinical-product roadmap. Software is one of ten gaps. It does not need to be the one that determines your timeline.

Making the decision

This is not a technology decision. It is a capital allocation decision.

You have a fixed amount of engineering talent, a fixed amount of capital, and a fixed amount of time before your competitive window closes or your runway expires. The question is not "can we build clinical workflow software?" The question is "should we allocate our constrained resources to building it, or to the activities that only we can do?"

No vendor can run your clinical validation study. No platform can write your FDA submission. No consultant can develop your classification model. Those activities require your specific scientific expertise.

Instrument integration, HL7 message generation, audit trail infrastructure, and multi-site deployment are general-purpose problems. They are the same whether you are doing FTIR pathogen identification, Raman tissue classification, or NIR blood analyte measurement. They have been solved before. Using a solved solution is not a compromise — it is engineering discipline.

Map the iceberg. Count the real costs. Allocate your resources to the work that only you can do. You can explore the platform approach at SpectraDx Solutions to see what that looks like in practice.